TB-500 legal status, the FDA 503A category, and how compounded access actually works.

TB-500 legal status, stated plainly

The TB-500 legal status today rests on one FDA action and one FDA list entry. FDA lists this substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," and placed it in 503A "Category 2" — bulk drug substances that may present significant safety risks — effective with FDA's September 29, 2023 update to the list of substances nominated for use under section 503A ^[16]. FDA's stated rationale included potential immunogenicity for certain routes of administration and a lack of important safety information ^[16].

Three consequences follow directly, and this page does not stretch any of them. As a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding ^[18]. It is not an FDA-approved drug ^[16]. And FDA's own list entry is what establishes the identity link readers ask about: TB-500 is the LKKTETQ fragment associated with thymosin beta-4 ^[16]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.

Access may expand in 2026 — but here is exactly what is, and is not, true

The forward-looking part of this story is real, and it is worth stating with momentum: TB-500 is under active FDA review, and access could change in 2026. The anchor fact is concrete and citable. "TB-500 (free base)" and "TB-500 acetate" are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[17]. The same agenda also lists BPC-157, KPV, and MOTs-C ^[17].

Now the discipline. A scheduled PCAC discussion is a step in evaluation — advisory input that FDA weighs — and nothing more. It is not a listing decision, not a reclassification, and not a change in current status ^[17]. Inclusion on a final 503A bulks list is decided by FDA rulemaking, informed by PCAC; being on the agenda means the question is open, not answered ^[18]. No outcome should be assumed, stated, or dated. That a substance under review is still on a "being considered" agenda is, if anything, consistent with its evaluation being ongoing rather than resolved.

For completeness and against the rumors: some commercial and clinic sources have reported an early-2026 expectation that a group of Category 2 peptides would move back toward Category 1, and others have asserted specific 2026 dates on which TB-500-related entries were "removed." None of those claims could be confirmed from an authoritative FDA source, so this page does not treat any reclassification or removal as having occurred ^[18]. The status above is the last FDA action confirmable from FDA.gov.

Is TB-500 FDA Approved?

No. TB-500 is not approved by the FDA for human use and has no approved therapeutic indication ^[16]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and TB-500 is neither an approved drug nor, currently, a bulk substance within FDA's enforcement-discretion policy for 503A compounding ^[18].

How legally compounded peptide access works

Compounding in the U.S. runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[18].

In practice the lawful pathway is a sequence. A patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The preparation is then dispensed by a state-licensed 503A pharmacy, or, for office or batch use, sourced from a 503B outsourcing facility ^[18]. Telehealth is one channel for that prescriber-evaluation step; it does not change which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[18].

The ingredient-eligibility caveat is where TB-500 sits. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[18]. A substance FDA has flagged for significant safety risks — a Category 2 substance — is not eligible for routine 503A compounding while that status stands ^[18]. This describes the framework in general terms only; it names no pharmacy, clinic, telehealth provider, or vendor, and it is not a route to obtaining any substance.

What Is the FDA 503A Status of TB-500?

FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — effective with its September 29, 2023 nominated-substances update, citing potential immunogenicity for certain routes and a lack of important safety information ^[16]. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding ^[18]. "TB-500 (free base)" and "TB-500 acetate" are on the agenda of the July 23-24, 2026 PCAC meeting as candidates being considered for the 503A bulks list — a scheduled discussion, not a decision ^[17].

Can You Get TB-500 From a Compounding Pharmacy?

TB-500 is not an FDA-approved drug, and as a 503A Category 2 substance it is not eligible for routine 503A compounding while that status stands ^[16][18]. The lawful access framework — licensed-prescriber evaluation, a valid patient-specific prescription, and a 503A pharmacy or 503B outsourcing facility — applies generally, but only to ingredients that are eligible under the bulk-substance rules ^[18]. This page describes that framework in general terms and names no pharmacy, clinic, or vendor.

Is TB-500 Legal?

TB-500 is not FDA-approved for human use and is classified by FDA as a 503A Category 2 bulk substance, outside FDA's enforcement-discretion policy for compounding ^[16][18]. It is prohibited by the World Anti-Doping Agency, and is classified as a prescription medicine in some jurisdictions ^[10]. It is sold by research suppliers for laboratory use, not as an approved medicine for human consumption.

Is TB-500 Banned by WADA?

Yes. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited peptide/growth-factor and tissue-repair categories, banned in and out of competition for the relevant classes, and are detectable by LC-MS anti-doping assays in equine and human matrices ^[10]. The detection science is mature precisely because the substance has been a doping-control target.

Why Is TB-500 Used in Racehorses?

TB-500 was encountered as a designer drug in racehorses, which prompted the first equine LC-MS detection methods (with limits of detection around 0.01-0.02 ng/mL) to control its misuse in equine sport ^[10]. Its presence in racing is a doping-control concern, not an approved veterinary indication.

How Long Does TB-500 Stay in Your System?

No validated human clearance window is published for the TB-500 heptapeptide ^[10]. The detectability question has been answered for anti-doping purposes — LC-MS assays characterized TB-500 and its metabolites in equine and in-vitro matrices for detection ^[10] — but that is a detection method, not a human pharmacokinetic half-life. For the PK that does exist, on the full-length protein, see TB-500 half-life and pharmacokinetics.